# Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression.

> PubMed lists PMID 41816810 in Diabetes, obesity & metabolism as Journal Article, Review, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41816810-glucagon:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-18
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41816810-glucagon/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41816810-glucagon-v1.json
- Content SHA-256: `04d505167e7e59b0b6d3f3d98ffb65316ee28c27c79a4f3d6bf156f6d1a91b03`

## Claims and source pins

### Headline

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. ([`pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317`](#source-pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317))

### Summary

PubMed lists PMID 41816810 in Diabetes, obesity & metabolism as Journal Article, Review, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317`](#source-pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317))

### Paragraph 1

PubMed lists PMID 41816810 in Diabetes, obesity & metabolism as Journal Article, Review, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317`](#source-pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317`](#source-pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317))

## Sources

<a id="source-pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317"></a>
- **Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. · retained source version 1:2026-07-18:current:8487f02e73170f1cb7089446390f7333b900b3796337b74a28372d5ad00e1722** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41816810/) (`pubmed-observation-pmid-41816810-2026-07-18-8487f02e7317`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41816810-glucagon-v1.json SHA-256: 04d505167e7e59b0b6d3f3d98ffb65316ee28c27c79a4f3d6bf156f6d1a91b03.